ISSN: 2578-4838
Authors: Parate R* and Shah N
Background: Several long-term health consequences are seen in patients with COVID-19, with some symptoms persisting for months after resolution of the infection. Weakness and muscle fatigue are reported to be the most common persistent symptoms. However, there is no specific medication for post-viral fatigue. Case Discussion: Eight patients experiencing fatigue post discharge from COVID-19 hospitalization were included in the case study. Of these, one patient each experienced muscle pain and nausea, in addition to fatigue; 2 had comorbid conditions and reported concomitant medications. Vitals were stable in patients throughout the study. Patients were treated with ImmunoSEB (BD) and ProbioSEB CSC3 (OD) for 14 days. The supplemental treatment resulted in a significant improvement (p < 0.001) in fatigue as assessed by the Chalder Fatigue Scale (CFQ-11) scores on days 5 (17.13), 7 (12.38), 10 (7.63), 12 (4.38), and 14 (2.75) as compared to the post-COVID baseline (26.63). All patients reported no more than usual or less than usual fatigue at the end of the 14 days treatment period. No adverse events were reported. Conclusion: The present cases demonstrate that a 14 days supplementation of ImmunoSEB + ProbioSEB CSC3 significantly reduces post-COVID-19 fatigue in patients. The proposed supplement regimen could be a potential tool to aid in the recovery of COVID-19 patients, many of whom continue to experience severe fatigue several months after initial infection. A large-scale, placebo-controlled prospective study is warranted to further evaluate this effect.
Keywords: SARS-CoV-2 infection; COVID-19 disease; Fatigue; Chalder Fatigue Scale; ImmunoSEB + ProbioSEB CSC3
